SOURCE: eLocity Inc.

July 26, 2005 07:10 ET

July 26th Stock Trading Alert

NOTE TO EDITORS: The Following is an Investment Opinion Being Issued by eLocity Inc.

SARASOTA, FL -- (MARKET WIRE) -- July 26, 2005 -- eLocity's stocks to watch for Tuesday are -- GeneThera (OTC BB: GTHA), LifeCell Corp. (NASDAQ: LIFC), Teva Pharmaceutical (NASDAQ: TEVA), DNAPrint genomics, Inc. (OTC BB: DNAG)

Investors, have a look at GeneThera (OTC BB: GTHA), a molecular biotechnology company that currently provides genetic diagnostic solutions for the veterinary and agricultural industries, with future plans to include the health-care industry. On Monday, the company announced its strategic alliance partnership with Nutricion Avanzada of Monterrey, Mexico, a large private multinational distributor of nutritional supplements for animals with access to large amounts of cattle throughout Mexico.

GeneThera said the agreement between the companies allows access for Nutricion Avanzada to GeneThera's proprietary diagnostic solution based on its genetic expression assay, GEA™. GeneThera will gain access to Nutricion Avanzada's customer base as well as gain a physical presence in Mexico at Nutricion Avanzada's Monterrey facilities, the company said.

Shares of GeneThera (OTC BB: GTHA) are currently trading at around $0.77.

Other stocks in the news:

LifeCell Corp. (NASDAQ: LIFC)

LifeCell Corporation reported financial results for the second quarter Monday, reporting total revenues of $22.7 million compared to $15.1 million for the second quarter of 2004. LifeCell Corp. also said Monday that profit more than tripled in the second quarter due to increased demand for its AlloDerm skin-graft material and a tax break.

LIFC closed Monday's regular trading session at $20.38.

Teva Pharmaceutical (NASDAQ: TEVA)

Teva Pharmaceutical announced Monday morning that it has agreed to acquire IVAX Corp. for $7.4 billion, giving Teva Pharmaceutical the rights to make generic copies of several brand-name drugs.

TEVA closed Monday's regular trading session at $31.23.

DNAPrint genomics, Inc. (OTC BB: DNAG)

DNAPrint genomics announced a new corporate marketing and product branding campaign on Monday, focused on the Company's four distinct markets, pharmacogenomics and test/drug combinations, forensics technology for law enforcement, consumer family heritage tests and genotyping services for pharmaceutical companies and universities.

DNAG closed Monday's trading session at $0.113.

About eLocity Inc: eLocity owns and operates three financial websites for investors., Featuring active message boards for the penny stock trader, rumors and more., Visit this site for our daily top stock "GRID Makers." We rank stocks on volume, message board activity, sentiment and trend forecast., Bell2Bell features news stories, rumors, the InvestBoard and more.

Sign up for FREE at any of the sites above.

The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company." The company received compensation for newsletter and ad services for GTHA (Public Company). The compensation is one thousand dollars from a non-affiliated third party. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.

The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.

The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

Contact Information

  • Contact:
    eLocity Inc.
    Thomas Clay